UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

The clinical trial was designed as a single-arm, open-label clinical study, with the main purpose of exploring the safety, pharmacokinetics, and best recommended dose (RP2D) of the UTAA17 injection in the treatment of relapsed or refractory multiple myeloma (r/r MM) subjects, and also the efficacy will be observed. Eligible subjects will accept the infusion of UTAA17 injection after pretreatment, and their blood will be collected before and after infusion for evaluation of pharmacokinetics, immunogenicity and safety. This study plans to evaluate efficacy using the revised Evaluation of Efficac

Trial Details

NCT ID
NCT06279026
Phase
NA
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • UTAA17 Injection
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • All subjects or legal representatives must sign an informed consent form approved by the Ethics Committee in person before commencing any screening…
  • ≥18 years old, regardless of gender, diagnosed with relapsed or refractory multiple myeloma according to the Efficacy Evaluation Criteria for multi…
  • The presence of measurable lesions at the time of screening will be determined according to any of the following criteria:
  • Monoclonal plasma cells in bone marrow ≥ 10%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →